# The Weigh Forward Supports Weight-Management Initiatives

This comprehensive program supports health systems in understanding obesity's impact on their population and provides recommendations for weight-management initiatives for appropriate individuals.

## The program consists of 4 impactful modules:



### Module 1: Expanding the Quadruple Aim

• Designed to help health systems understand the impact of obesity on their populations. It provides an overview of weight-management guidelines and treatment options, including lifestyle management, FDA-approved treatments such as AOMs, and surgical interventions



### Module 2: Know Your Numbers

• Explores obesity-related comorbidities, risk assessment, EHR coding for obesity, and potential action steps for health systems for employees/patient populations



### Module 3: Act Now

- Provides an overview of clinical practice guidelines for managing obesity and offers a measurement framework to assess and quantify the impact of implemented obesity care pathways
- Discusses approaches for developing obesity care pathways and reviews the steps providers may need to take to secure health plan coverage for AOMs



#### Module 4: Case Studies and Resources

- Presents 4 AMGA health system case studies that highlight successful AOM coverage
- Explores resources available from Novo Nordisk for advancing obesity care considerations for patients, providers, and health systems

This program is important because it provides considerations for implementing clinical care pathways for obesity.



To learn more about the program resources and tools go to www.novonordiskworks.com

AMGA=American Medical Group Association; AOM=anti-obesity medication; EHR=electronic health record; FDA=U.S. Food and Drug Administration.



Novo Nordisk is a registered trademark of Novo Nordisk A/S.